Johnson & Johnson (JNJ.N)
23 Jan 2015
NEW YORK - Lawyers for thousands of women suing Johnson & Johnson’s Ethicon Inc over transvaginal mesh devices are fighting back against the company’s claim that illegal phone solicitations may have resulted in baseless lawsuits.
NEW YORK, Jan 23 - Lawyers for thousands of women suing Johnson & Johnson's Ethicon Inc over transvaginal mesh devices are fighting back against the company's claim that illegal phone solicitations may have resulted in baseless lawsuits.
LONDON - FIFA have rejected suggestions that major sponsors were cutting their ties with the organisation because it was a "toxic brand", saying on Friday that they were in advanced negotiations with new sponsors eager to replace the old.
NEW YORK, Jan 21 - For more than eight years, Johnson & Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial - and ultimately ill-fated - bidding war for device maker Guidant.
Jan 20 - Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.
Jan 20 - Johnson & Johnson reported lower-than-expected quarterly sales as a stronger dollar offset higher sales of the Band-Aid maker's new drugs and older treatments.
Jan 20 - Johnson & Johnson reported a slightly better-than-expected quarterly profit as surging sales of new drugs and mainstay older brands offset weak demand for medical devices and consumer healthcare products.
LONDON - Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.
LONDON, Jan 16 - Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.
- Depomed Inc on Thursday said it has agreed to pay $1.05 billion to acquire the U.S. rights to Johnson & Johnson's Nucynta opioid pain drug franchise, giving the smaller company a new flagship product expected to significantly add to revenue and earnings.
|General Electric Company (GE.N)||$24.48||+0.20|
|Procter & Gamble Co (PG.N)||$90.08||-1.54|
|Pfizer Inc. (PFE.N)||$32.45||-0.36|
|Novartis AG (NOVN.VX)||CHF85.50||+1.20|
|Merck & Co., Inc. (MRK.N)||$62.49||-0.10|
|Medtronic, Inc. (MDT.N)||$76.95||+1.47|
|Baxter International Inc. (BAX.N)||$71.43||-0.83|
|Stryker Corporation (SYK.N)||$92.70||-0.67|
|Boston Scientific Corporation (BSX.N)||$14.84||-0.09|
|Zimmer Holdings, Inc. (ZMH.N)||$116.98||-1.37|